Adela
Adela is developing advanced blood test technology to improve cancer diagnosis and management, with locations in Toronto and San Francisco.
Company History
Adela, initially backed with $60M in Series A Financing, was developed to bring breakthrough approaches to blood-based detection of cancer and other diseases. The genome-wide methylation enrichment technology that Adela utilizes was originally developed at University Health Network’s Princess Margaret Cancer Centre. Adela debuted with the mission to provide accessible and innovative blood tests harnessing biology to revolutionize cancer care, accelerating diagnosis, and improving disease management.
Blood Tests and Cancer Diagnosis
Adela is pioneering the development of blood tests to accelerate the diagnosis and improve the management of cancer. The core of their technology lies in a genome-wide methylome enrichment platform that captures comprehensive information from the entire methylome. This platform maximizes test performance, making significant advancements in early cancer detection and well-informed treatment decisions. Adela's blood tests are designed for minimal residual disease (MRD) monitoring, utilizing a tissue agnostic approach which reduces the need for tumor samples.
Technology and Platform
Adela's innovative genome-wide methylome enrichment platform functions by efficiently mining the entire methylome, detecting signals of early disease with high sensitivity. The technology is being developed for use in monitoring minimal residual disease (MRD) and early detection of multiple cancers (MCED). This tissue agnostic approach simplifies the process by eliminating the need for obtaining tumor samples, thus broadening the platform's applicability across different cancer types.
Funding and Financial Backing
Adela received significant financial backing to further its innovative platform. The company secured $48 million in Series A1 financing from Labcorp to advance its methylation-based head and neck cancer test. Adela initially raised $60 million in Series A Financing at its debut to support the development of its cutting-edge technology focused on blood-based cancer detection.
Research and Development Initiatives
Adela is actively engaged in research and development to enhance their cancer detection and management technologies. At the American Association for Cancer Research Annual Meeting 2024, Adela presented data on their MRD test's ability to inform adjuvant treatment decisions and monitor recurrence in head and neck cancer patients. Additionally, they demonstrated strong early-stage cancer detection capabilities at the 2023 meeting. The company has also enrolled participants in a multi-center study to support the validation of its genome-wide methylome enrichment platform for early cancer detection.